India is facing a serious thalassemia drug shortage, prompting the government to seek an explanation from Novartis while exploring generic alternatives to stabilize supply. The issue centers on Desferal, a life-saving treatment used by...
India is facing a growing public health concern as energy drinks are increasingly being linked to liver damage in young adults. Doctors across the country report a noticeable rise in patients in their 20s and 30s showing early signs of liver...
A Gujarat-based non-governmental organisation has called on the Centre to bring nutraceuticals regulation India under stricter drug control, raising concerns about product quality issues, consumer safety risks, and pricing concerns in healthca...
Rusan Pharma has achieved a significant global milestone by receiving Good Manufacturing Practice (GMP) approval from Pharmaceuticals and Medical Devices Agency (PMDA), one of the world’s most stringent drug regulators.
Eli Lilly is in advanced discussions to acquire Kelonia Therapeutics in a deal valued at more than $2 billion, signaling a strong push into next-generation cancer treatments.
Hyderabad-based Aurobindo Pharma has received final approval from the U.S. Food and Drug Administration (USFDA) for its generic version of glycerol phenylbutyrate oral liquid, strengthening its presence in the US generics market.
In a major move to control rising healthcare costs, the Centre has asked states to Uniform Hospital Rates across public and private healthcare facilities. The push aims to reduce wide price differences for the same treatments, which have been...
India may see a rise in medicine prices as the West Asia conflict drives up raw material and logistics costs, impacting pharma companies and raising concerns over supply and affordability.
World Liver Day 2026 highlights a growing concern—liver damage is no longer driven by alcohol alone.Experts say everyday choices around food, sleep, and stress are now major contributors to declining liver health.
Roche has announced a fresh clinical push for its gene therapy as it rolls out a new Elevidys study aimed at addressing concerns raised by European regulators. The move comes after the therapy failed to secure approval in Europe, prompting the...